prostate cancer

Role of molecular biomarkers in localized prostate cancer
Hypofractionated IMRT outcomes comparable to standard regimen“We showed that we can safely compress radiation into a shorter time frame, into fewer treatments, at higher dose per fraction, with similar clinical outcomes and similar toxicity profiles,” said researcher Michael Wang, MD.
AUA 2017: A small-town plumber’s 10 can’t-miss sessionsIn preparation for the AUA annual meeting in May, urologist Henry Rosevear, MD, shares the 10 sessions he’s looking forward to the most.
Researchers validate prognostic model for mCRPCResearchers have developed and validated a clinically useful prognostic model for men with metastatic castration-resistant prostate cancer, which can be used in the front-line setting.
Day of RP affects complication rates, length of stayRadical prostatectomy performed on a Friday is associated with a higher complication rate and extended hospital stay compared with the same surgery performed on other days of the week.
Genetic predictors could improve PSA accuracyA recent study has found that genetic predictors of normal PSA levels in healthy men could be used to improve the accuracy of PSA-based prostate cancer screening.
Urology FDA approvals of 2016Urology-related FDA approvals from 2016 encompassed drugs and devices for prostate cancer, renal cell carcinoma, bladder cancer, stone disease, and more.
Salvage LND: Complete PSA response achievableSalvage lymph node dissection results in an immediate complete PSA response in about one-third of patients with rising PSA and nodal recurrence following local therapy for prostate cancer, according to German researchers.
When is a patient cured after prostatectomy?"Rather than making a blanket statement regarding continued follow-up, we need to consider the pathologic features commonly known to increase the risk of [prostate cancer] recurrence—concurrent medical problems, the patient’s age at recurrence, PSA doubling time, longevity in the family, etc," writes J. Brantley Thrasher, MD.
Biochemical recurrence risk high 10 years post-RPThe risk for biochemical recurrence of prostate cancer remains relatively high even 10 years after radical prostatectomy, but it does not appear to be influenced by a positive family history of prostate cancer or a family or personal history of other cancer, according to a study analyzing data from the prospective German Familial Prostate Cancer database.